Abstract
Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 285-293 |
| Number of pages | 9 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - Aug 21 2013 |
Fingerprint
Keywords
- Efficacy
- Mechanism of action
- Perampanel
- Review
ASJC Scopus subject areas
- Pharmacology (medical)
- Medicine(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
- Safety Research
- Chemical Health and Safety
Cite this
New drug classes for the treatment of partial onset epilepsy : Focus on perampanel. / Shih, Jerry J.; Tatum, William O.; Rudzinski, Leslie Ann.
In: Therapeutics and Clinical Risk Management, Vol. 9, No. 1, 21.08.2013, p. 285-293.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - New drug classes for the treatment of partial onset epilepsy
T2 - Focus on perampanel
AU - Shih, Jerry J.
AU - Tatum, William O.
AU - Rudzinski, Leslie Ann
PY - 2013/8/21
Y1 - 2013/8/21
N2 - Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.
AB - Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.
KW - Efficacy
KW - Mechanism of action
KW - Perampanel
KW - Review
UR - http://www.scopus.com/inward/record.url?scp=84881582057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881582057&partnerID=8YFLogxK
U2 - 10.2147/TCRM.S37317
DO - 10.2147/TCRM.S37317
M3 - Review article
VL - 9
SP - 285
EP - 293
JO - Therapeutics and Clinical Risk Management
JF - Therapeutics and Clinical Risk Management
SN - 1176-6336
IS - 1
ER -